STOCK TITAN

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
partnership clinical trial

BrainStorm Cell Therapeutics has signed a Memorandum of Understanding (MOU) with Pluri to manufacture NurOwn® for the planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This agreement will enable BrainStorm to transfer its manufacturing technology and start production at Pluri's GMP-compliant facility in Israel upon finalizing a definitive agreement. The collaboration aims to meet the supply requirements for the Phase 3b trial and explore future commercial distribution options, pending NurOwn's approval. The trial will enroll up to 200 participants and is designed in two parts: a 24-week double-blind period followed by a 24-week open-label period. The primary endpoint is the change in ALSFRS-R score from baseline to week 24. BrainStorm will provide further updates in Q4 2024.

BrainStorm Cell Therapeutics ha firmato un Memorandum of Understanding (MOU) con Pluri per la produzione di NurOwn® per il previsto trial di Fase 3b sulla sclerosi laterale amiotrofica (ALS). Questo accordo permetterà a BrainStorm di trasferire la sua tecnologia di produzione e avviare la produzione presso la struttura conforme alle GMP di Pluri in Israele, dopo la finalizzazione di un accordo definitivo. La collaborazione ha l'obiettivo di soddisfare i requisiti di fornitura per il trial di Fase 3b e di esplorare future opzioni di distribuzione commerciale, in attesa dell'approvazione di NurOwn. Il trial prevede l'arruolamento di fino a 200 partecipanti ed è suddiviso in due parti: un periodo doppio cieco di 24 settimane seguito da un periodo a etichetta aperta di 24 settimane. L'obiettivo principale è la variazione del punteggio ALSFRS-R dal basale alla settimana 24. BrainStorm fornirà ulteriori aggiornamenti nel quarto trimestre del 2024.

BrainStorm Cell Therapeutics ha firmado un Memorando de Entendimiento (MOU) con Pluri para fabricar NurOwn® para el ensayo de fase 3b planificado en esclerosis lateral amiotrófica (ALS). Este acuerdo permitirá a BrainStorm transferir su tecnología de fabricación y comenzar la producción en la instalación de Pluri, que cumple con las GMP en Israel, tras la finalización de un acuerdo definitivo. La colaboración se propone satisfacer los requisitos de suministro para el ensayo de fase 3b y explorar futuras opciones de distribución comercial, a la espera de la aprobación de NurOwn. El ensayo incluirá hasta 200 participantes y está diseñado en dos partes: un período doble ciego de 24 semanas seguido de un período abierto de 24 semanas. El objetivo principal es el cambio en la puntuación ALSFRS-R desde la línea de base hasta la semana 24. BrainStorm proporcionará más actualizaciones en el cuarto trimestre de 2024.

BrainStorm Cell TherapeuticsPluri와 함께 근위축성 측삭 경화증(ALS)을 위한 계획된 3b 단계 시험에서 NurOwn®을 제조하기 위한 양해각서(MOU)를 체결했습니다. 이 협약은 BrainStorm이 제조 기술을 이전하고 최종 계약이 체결되는 대로 이스라엘 Pluri의 GMP 준수 시설에서 생산을 시작할 수 있도록 합니다. 이번 협력의 목표는 3b 단계 시험의 공급 요구 사항을 충족하고 NurOwn의 승인 대기 중 향후 상업적 유통 옵션을 탐색하는 것입니다. 시험은 최대 200명의 참가자를 등록하고 두 부분으로 설계되었습니다: 24주간의 이중 맹검 기간과 24주간의 공개 라벨 기간입니다. 주요 목표는 기준선에서 24주까지 ALSFRS-R 점수의 변화입니다. BrainStorm은 2024년 4분기에 추가 업데이트를 제공할 예정입니다.

BrainStorm Cell Therapeutics a signé un protocole d'accord (MOU) avec Pluri pour fabriquer NurOwn® pour l'essai de phase 3b prévu sur la sclérose latérale amyotrophique (ALS). Cet accord permettra à BrainStorm de transférer sa technologie de fabrication et de commencer la production dans l'installation conforme aux BPF de Pluri en Israël après la finalisation d'un accord définitif. La collaboration vise à répondre aux besoins en approvisionnement pour l'essai de phase 3b et à explorer les options de distribution commerciale futures, en attendant l'approbation de NurOwn. L'essai recrutera jusqu'à 200 participants et est conçu en deux parties : une période double aveugle de 24 semaines suivie d'une période ouverte de 24 semaines. L'objectif principal est le changement du score ALSFRS-R entre le point de départ et la semaine 24. BrainStorm fournira d'autres mises à jour au quatrième trimestre 2024.

BrainStorm Cell Therapeutics hat ein Memorandum of Understanding (MOU) mit Pluri unterzeichnet, um NurOwn® für die geplante Phase-3b-Studie zur amyotrophen Lateralsklerose (ALS) herzustellen. Diese Vereinbarung wird es BrainStorm ermöglichen, seine Fertigungstechnologie zu übertragen und die Produktion in der GMP-konformen Einrichtung von Pluri in Israel aufzunehmen, sobald ein endgültiger Vertrag abgeschlossen ist. Die Zusammenarbeit zielt darauf ab, die Versorgungsanforderungen für die Phase-3b-Studie zu erfüllen und zukünftige Optionen für den kommerziellen Vertrieb in Abhängigkeit von der Genehmigung von NurOwn zu erkunden. Die Studie wird bis zu 200 Teilnehmer einschließen und ist in zwei Teile unterteilt: eine 24-wöchige Doppelblindphase, gefolgt von einer 24-wöchigen offenen Phase. Der primäre Endpunkt ist die Veränderung des ALSFRS-R-Scores vom Ausgangswert bis zur Woche 24. BrainStorm wird im 4. Quartal 2024 weitere Updates bereitstellen.

Positive
  • BrainStorm has secured a manufacturing partner in Pluri for the Phase 3b trial of NurOwn.
  • The collaboration ensures GMP-compliant production capacity for the trial.
  • The trial design includes a robust 200-participant enrollment, with clear efficacy endpoints.
  • Successful completion of Part A may accelerate regulatory approval via a Biologics License Application (BLA).
Negative
  • The agreement is still pending finalization of a binding definitive agreement.

Insights

The MOU with Pluri represents a strategically important manufacturing partnership for BrainStorm's NurOwn ALS therapy. The planned Phase 3b trial involving 200 participants is designed with a robust dual-part structure - a 24-week placebo-controlled phase followed by an open-label extension. This manufacturing agreement is important for several reasons:

The proximity of Pluri's GMP-compliant facility to BrainStorm's R&D team in Israel offers significant operational advantages for quality control and technology transfer. The partnership also provides manufacturing scalability potential for future commercial production, should NurOwn receive regulatory approval.

The trial's design using ALSFRS-R as the primary endpoint aligns with regulatory requirements and previous ALS studies. This positions BrainStorm for a potential BLA submission following successful completion of Part A, which could accelerate the pathway to commercialization.

Memorandum of Understanding has been signed

NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facility upon finalizing the binding definitive agreement.

BrainStorm_Logo

Under the terms of the proposed agreement, Pluri will provide GMP-compliant manufacturing of NurOwn at its facilities in Israel. This collaboration aims to fulfill essential supply requirements of NurOwn® as BrainStorm advances its Phase 3b clinical trial. Additionally, the two companies are exploring options for manufacturing to support potential future commercial distribution, pending approval of NurOwn.

"Pluri has become a recognized leader in GMP-compliant clinical manufacturing of cell-based products, known for their exceptional quality standards and strict regulatory compliance," said Haro Hartounian, PhD, Chief Operating Officer at BrainStorm. "Pluri will offer manufacturing capacity to support our Phase 3b clinical trials, in addition to our existing development and clinical manufacturing activities at The Center for Advanced Cellular Therapies (I-ACT) in Israel. We believe that having Pluri's clinical manufacturing facility near BrainStorm's manufacturing and R&D teams will strengthen communication and foster a highly productive collaboration."

Chaim Lebovits, President and CEO of Brainstorm, added, "The Phase 3b clinical trial marks a critical step toward potential regulatory approval of NurOwn, "This MOU with Pluri creates a strong foundation to meet the clinical supply requirements of NurOwn®. The proposed agreement also offers the prospect of establishing an attractive supply arrangement that aligns well with our strategic priorities as we prepare for the operational and financial commitments of the Phase 3b trial."

Yaky Yanay, CEO and President of Pluri commented, "We applaud BrainStorm for their commitment to developing a novel cell therapy for ALS. We are eager to utilize our proprietary knowledge, long years of experience and manufacturing capabilities to support their mission of bringing hope to patients and families impacted by this devastating disease."

The Phase 3b trial has been designed to enroll up to approximately 200 participants with ALS. It will be conducted in two parts: In Part A, participants will receive 3 doses of NurOwn or placebo for 24 weeks. This will be followed by an open label period, during which patients from both arms will receive 3 doses NurOwn for another 24 weeks (Part B). The primary efficacy endpoint will be a comparison of change in ALSFRS-R from baseline to week-24 (i.e. at the end of Part A) for NurOwn vs. placebo. Successful completion of Part A of the double-blind Phase 3b study will position BrainStorm to submit a Biologics License Application (BLA) for regulatory approval, potentially accelerating the path to market.

BrainStorm plans to hold a conference call for investors later in Q4 2024, during which it will provide further updates on the NurOwn Phase 3 clinical program.

About NurOwn®

The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are harvested from each person with ALS and are manufactured using an innovative and proprietary process, to secrete neurotrophic factors to target specific neurodegenerative diseases. The lead program for NurOwn is for the treatment of ALS. BrainStorm's long-term commitment to ALS is demonstrated in preclinical research and a series of clinical studies, all of which have been published in peer-reviewed journals.

The NurOwn clinical program has generated valuable insights into the pathology of ALS, as well as disease progression and treatment. Since the initial Phase 3 readout, BrainStorm has shared the full dataset through rigorous peer-reviewed analysis, including: quantification of Floor Effect, which had been noted, but never before explored in depth; evaluation of multiple pre-specified biomarkers, collected at seven different points across 20 weeks during the trial, allowing a longitudinal view; and analysis of genetic data, which represents one of the first ALS trials to prospectively invoke pharmacogenomic analysis of clinical outcome, offering great promise for the development of future treatments for ALS.

About Pluri Inc.

Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company's technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. PluriCDMO™ offers CDMO services to companies from early preclinical development, through late-stage clinical trials and commercialization, with a mission to deliver high-quality, essential therapies to patients. . Pluri establishes partnerships that leverage the Company's proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989), and another grant from the ALS Association and I AM ALS. BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS).

Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), ADCOM meeting related to NurOwn, the timing of a PDUFA action date for the BLA for NurOwn, the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Media
Lisa Guiterman
Phone: +1 202-330-3431
lisa.guiterman@gmail.com 

IR:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com 

Logo: https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

 

Cision View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-and-pluri-partner-to-support-nurown-phase-3b-trial-manufacturing-302300993.html

SOURCE BrainStorm Cell Therapeutics Inc.

FAQ

What is the purpose of the MOU between BrainStorm and Pluri?

The MOU aims to manufacture NurOwn for BrainStorm's Phase 3b trial in ALS and explore future commercial distribution options.

When will BrainStorm provide further updates on the Phase 3b trial?

BrainStorm plans to provide further updates in Q4 2024.

What is the primary efficacy endpoint of the Phase 3b trial for NurOwn?

The primary efficacy endpoint is the change in ALSFRS-R score from baseline to week 24.

How many participants will be enrolled in the Phase 3b trial?

The trial is designed to enroll up to approximately 200 participants with ALS.

What are the two parts of the Phase 3b trial?

Part A involves a 24-week double-blind period with 3 doses of NurOwn or placebo, followed by Part B, a 24-week open-label period with 3 doses of NurOwn for all participants.

Brainstorm Cell Therapeutics Inc.

NASDAQ:BCLI

BCLI Rankings

BCLI Latest News

BCLI Stock Data

6.90M
5.23M
9.04%
13.9%
2.07%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK